Windlas BiotechNSE:WINDLAS -0.19%89 Net Margin % is 6.70% as of Mar. 2026, which is 18% below its 10-year median of 8.13. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.27 (Fairly Valued). The stock has 1 warning sign investors should review. Among 956 Drug Manufacturers companies, Windlas Biotech ranks better than 56.17% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Windlas Biotech's Net Income for the
three
months ended in Mar. 2026 was ₹160 Mil. Windlas Biotech's Revenue for the
three
months ended in Mar. 2026 was ₹2,385 Mil. Therefore, Windlas Biotech's net margin for the quarter that ended in Mar. 2026 was 6.70%.
The historical rank and industry rank for Windlas Biotech's Net Margin % or its related term are showing as below:
NSE:WINDLAS'
s Net Margin % Range Over the Past 10 Years
Min: 3.71 Med: 8.13 Max: 20.91
Current: 7.35
NSE:WINDLAS's Net Margin % is ranked better than 56.17% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:WINDLAS: 7.35
Windlas Biotech (NSE:WINDLAS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Windlas Biotech Net Margin % Related Terms
Windlas Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Net Margin % of 6.70% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Windlas Biotech and its competitors. This is 18% below median its historical median of 8.13. Over the past decade, Windlas Biotech's Net Margin % has ranged from 3.71 to 20.91. According to the industry distribution chart, Windlas Biotech ranks #419 out of 956 companies in the Drug Manufacturers industry, placing it in the top 43.8%.
Is Windlas Biotech's Net Margin % too high?
Windlas Biotech's current Net Margin % of 6.70% is 18% below median its 10-year median of 8.13. Over the past 10 years, this metric has ranged from a low of 3.71 to a high of 20.91. The Drug Manufacturers industry median Net Margin % is 5.56. Windlas Biotech's value of 6.70% is 20.5% above this industry median. Based on the distribution chart, Windlas Biotech ranks #419 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #419 out of 956 companies for Net Margin %. This puts Windlas Biotech in the upper half of its industry. The industry median Net Margin % is 5.56. Windlas Biotech's value of 6.70% is 20.5% above this benchmark. Historically, Windlas Biotech's own Net Margin % has ranged from 3.71 to 20.91 over the past decade. While the company's 10-year median is 8.13 vs. the industry median of 5.56, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Net Margin % of 6.70% is 20.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Net Margin % is 6.70%, which is 18% below median its own 10-year median of 8.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.27, compared to a current price of ₹855.75 — trading 8.6% below its estimated fair value. The current Net Margin % is 6.70%, which is 18% below median its 10-year median of 8.13 and 20.5% above the Drug Manufacturers industry median of 5.56. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Net Margin % is 6.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹855.75 is trading 8.6% below its estimated GF Value™ of ₹936.27.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Net Margin %: 6.70% (18% below median its 10-year median of 8.13)
GF Value™: ₹936.27 vs. price of ₹855.75 (8.6% below fair value)
Industry Position: 20.5% above the Drug Manufacturers median (#419 of 956)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
